Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?

被引:20
|
作者
Zhang, Chunlan
Huang, Xufei
Li, Jian [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Hematol, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
Light-chain amyloidosis; Pathogenesis; Molecular mechanism; Fibrillogenesis; Cytotoxicity; STEM-CELL TRANSPLANTATION; PRIMARY SYSTEMIC AMYLOIDOSIS; BETA-PEPTIDE DEPOSITION; AL PRIMARY AMYLOIDOSIS; HUMAN MESANGIAL CELLS; BENCE-JONES PROTEINS; HIGH-DOSE MELPHALAN; P-COMPONENT; CARDIAC INVOLVEMENT; ALZHEIMERS-DISEASE;
D O I
10.1016/j.blre.2017.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Amyloid light-chain (AL) amyloidosis is a plasma-cell dyscrasia, as well as the most common type of systematic amyloidosis. Pathogenic plasma cells that have distinct cytogenetic and molecular properties secrete an excess amount of amyloidogenic light chains. Assisted by post-translational modifications, matrix components, and other environmental factors, these light chains undergo a conformational change that triggers the formation of amyloid fibrils that overrides the extracellular protein quality Control system. Moreover, the amyloidogenic light-chain itself is cytotoxic As a consequence, organ dysfunction is caused by both organ architecture disruption and the direct cytotoxic effect of amyloidogenic light chains. Here, we reviewed the molecular mechanisms underlying this sequence of events that ultimately leads to AL amyloidosis and also discuss current in vitro and in vivo models, as well as relevant novel therapeutic approaches. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:261 / 270
页数:10
相关论文
共 50 条
  • [31] PATIENT EXPERIENCE WITH LIGHT CHAIN AMYLOIDOSIS: A SURVEY FROM THE AMYLOIDOSIS RESEARCH CONSORTIUM
    Lousada, I.
    Comenzo, R.
    Landau, H.
    Guthrie, S.
    Merlini, G.
    HAEMATOLOGICA, 2015, 100 : 507 - 507
  • [32] Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium
    Lousada, Isabelle
    Comenzo, Ray
    Landau, Heather
    Guthrie, Spencer
    Merlini, Giampaolo
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (08) : S63 - S63
  • [33] Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
    Isabelle Lousada
    Raymond L. Comenzo
    Heather Landau
    Spencer Guthrie
    Giampaolo Merlini
    Advances in Therapy, 2015, 32 : 920 - 928
  • [34] Glycosylation of Immunoglobulin Light Chains is Associated with Amyloidosis
    Milani, Paolo
    Barnidge, David
    Murray, David
    Kohlhagen, Mindy
    Sepiashivili, Lusia
    Merlini, Giampaolo
    Dispenzieri, Angela
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E104 - E104
  • [35] FREE LIGHT-CHAINS OF IMMUNOGLOBULINS IN AMYLOIDOSIS
    SOLLING, J
    SOLLING, K
    ACTA MEDICA SCANDINAVICA, 1979, 206 (04): : 283 - 287
  • [36] Glycosylation of immunoglobulin light chains associated with amyloidosis
    Omtvedt, LA
    Bailey, D
    Renouf, DV
    Davies, MJ
    Paramonov, NA
    Haavik, S
    Husby, G
    Sletten, K
    Hounsell, EF
    AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 2000, 7 (04): : 227 - 244
  • [37] Serum and Urine Light Chains in AL Amyloidosis
    Mead, G. P.
    Stubbs, P. D.
    Goodman, H. J. B.
    Hawkins, P. N.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S106 - S106
  • [38] Light chain cardiac amyloidosis in a nonagenarian
    Takahashi, Koji
    Yamashita, Mina
    Sakaue, Tomoki
    Enomoto, Daijiro
    Uemura, Shigeki
    Okura, Takafumi
    Ikeda, Shuntaro
    Senba, Takanori
    Saijo, Akira
    Yamamura, Nobuhisa
    Kitazawa, Sohei
    JOURNAL OF GERIATRIC CARDIOLOGY, 2022, 19 (01) : 83 - 89
  • [39] Treatment of immunoglobulin light chain amyloidosis
    Gertz M.A.
    Zeldenrust S.R.
    Current Hematologic Malignancy Reports, 2009, 4 (2) : 91 - 98
  • [40] Predicting survival in light chain amyloidosis
    Palladini, Giovanni
    Milani, Paolo
    Merlini, Giampaolo
    HAEMATOLOGICA, 2019, 104 (07) : 1294 - 1296